Exploring the evolutionary advantage of viral CD200 orthologs, the expression and role of CD200 in different biological settings, and previous studies investigating CD200-averse immunotherapy may help us better understand CD200/CD200R’s candidacy as a safe and suitable target for cancer therapy. This evidence concerns the gene CD200R1 and cancer.